(+)-Fluprostenol

Research use only, not for human use.

(+)-Fluprostenol, an analogue of prostaglandin F2 alpha, is a prostaglandin F2α receptor PTGFR agonist and decreases the expression of Oviductal glycoprotein 1 (OVGP1).

(+)-Fluprostenol, an analogue of prostaglandin F2 alpha, is a prostaglandin F2α receptor PTGFR agonist and decreases the expression of Oviductal glycoprotein 1 (OVGP1).(In Vivo):(+)-Fluprostenol(s.c. to rats on day 18 of pregnancy) increased cervical creep, or softness, by the following day. Doses of (+)-Fluprostenol 100-fold larger were necessary to increase uterine contractions. (+)-Fluprostenol produced falls in serum progesterone concentrations, increases in 20 alpha-dihydroprogesterone concentrations, no changes in oestradiol or relaxin concentrations and a reduction in the ovarian human chorionic gonadotrophin binding capacity in vitro. (+)-Fluprostenol was less potent in inducing cervical softness when administered per vaginam, and a dose which produced softening in pregnant rats was ineffective in ovariectomized steroid-maintained pregnant or pro-oestrous rats.

——

——

Fluprostenol, (+)- | (+)-Fluprostenol | Travoprost acid | AL-5848

GPCR/G Protein

Prostaglandin Receptor

——

——

——

54276-17-4

458.474

C23H29F3O6

>98% (HPLC)

In Vitro:?DMSO : 330 mg/mL (719.79 mM)

O[C@@H](COc1cccc(c1)C(F)(F)F)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years